Kyntra Bio's FG-3246 Shows Promising mCRPC Data in Phase 1b/2 Combo Study
Event summary
- Kyntra Bio's Phase 1b/2 study of FG-3246 + enzalutamide in mCRPC patients showed median rPFS of 7.0 months overall, 10.1 months in patients with only one prior ARPI.
- FG-3180 PET imaging agent demonstrated potential as a biomarker for patient selection, with higher tumor uptake trending towards higher PSA50 response rates.
- Combination therapy had a similar safety profile to FG-3246 monotherapy, with neutropenia risk mitigated by G-CSF prophylaxis.
- Phase 2 monotherapy trial of FG-3246 is on track for interim analysis in 2H 2026.
The big picture
Kyntra Bio's positive Phase 1b/2 data for FG-3246 in combination with enzalutamide positions the company in the competitive mCRPC space, where novel therapies targeting androgen receptor pathways are actively being developed. The potential of FG-3180 as a companion diagnostic could differentiate FG-3246 in a market where precision medicine approaches are increasingly valued. The upcoming Phase 2 monotherapy trial results will be critical in assessing the standalone potential of FG-3246.
What we're watching
- Biomarker Validation
- Whether FG-3180 can be validated as a reliable biomarker for patient selection in larger studies.
- Clinical Trial Progress
- The pace at which the Phase 2 monotherapy trial of FG-3246 will deliver interim results in 2H 2026.
- Regulatory Strategy
- How Kyntra Bio will position these data for potential regulatory approvals or partnership discussions.
Related topics